Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale…
20 Million Patients Benefit from da Vinci Surgery Globally
Achievement reflects the dedication of surgeons and care teams worldwide to improving…
Best Weight Loss Pills for 2026? FDA Approves First Oral GLP-1 as Patients Evaluate Wegovy, Zepbound, and Telehealth Access Pathways
Newark, DE, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The term "best" reflects…
Capilea Mexico Unveils New Insights on Surge of US Patients Choosing Mexico for Hair Transplants
Mexico: The New Hub for US Hair Transplants December 26, 2025 10:00…
Curium Announces First Commercial Doses of PYLCLARI for Patients with Prostate Cancer in Poland
PYLCLARI® provides solutions to a wider patient group across Poland where there…
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
- First patient in the world treated with Alpha DaRT® in the…
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of…
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful…
